Mobile App

Google Play Apple Store
New and Emerging Treatments for NASH
Certified CME/CNE Activity - Mini Modules
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease.

No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options. These educational Mini Modules will review the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Review one (or all) Mini Modules of interest. Claim AMA or ANCC credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Arun Sanyal
Arun Sanyal, MD
Charles Caravati Professor and Chair
Division of Gastroenterology, Hepatology and Nutrition
Department of Internal Medicine
School of Medicine
Virginia Commonwealth University



 


20
Supported by an independent educational grant from
Gilead Sciences Medical Affairs
Expired Activity
Mini Module
6157
LiverDisease